** Drug developer Vir Biotechnology's VIR.O shares rise 33.2% to $10.50 premarket
** Co says its drugs VIR-5818 and VIR-5500 showed compelling response in patients with various solid tumors during early-stage trials
** Says VIR-5818 showed tumor shrinkage in 50% of patients with various HER2 positive cancers
** HER2 is a protein that stimulates quick growth of cancer cells
** VIR says all 12 patients who took VIR-5500 showed a decline in prostate-specific antigen levels, which indicate the presence of prostate cancer
** Up to last close, stock down 25.6% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。